In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Current antiretroviral therapies suppress the ability of HIV-1 to copy itself, but they cannot completely eliminate the virus. Under these treatment conditions, HIV-1 enters a silent, or "latent", state that rapidly becomes active again as soon therapy is stopped. "Because of the stability of latent HIV-1 inside of infected T cells, lifelong antiretroviral therapy is required, raising concerns about adverse affects over decades of therapy, the evolution of resistance, and the financial burden of treatment," explains senior study author, Dr. Robert F. Siliciano, from the Johns Hopkins University School of Medicine. "Therefore, there is an urgent need for strategies to eradicate HIV-1 from infected individuals."
Previous research has suggested that reactivation of the latent HIV-1 is an important first step for complete elimination of the virus, but it is not clear whether the activated virus or the host immune response will then lead to elimination of the infected cells. In the current study, Siliciano and colleagues observed that infected T cells survived after the latent virus was reactivated. However, when the immune response of the host T cells was heightened before the virus was reactivated, the infected cells were efficiently eliminated.
"Our results suggest that reactivation of latent HIV-1 will not purge the latent viral reservoir and that stimulation of HIV-1-specific T cell responses prior to virus reactivation may be essential for viral eradication," concludes Siliciano. "Therefore, an appropriately timed vaccination that boosts the response of the immune system to HIV-1 may be critical for therapies that move beyond suppression of HIV-1 to true elimination."
Pseudomonas aeruginosa: Infection Risks, Challenges, and Breakthroughs for Health Care Professionals
September 19th 2024Pseudomonas aeruginosa, a highly virulent pathogen, poses significant risks to immunocompromised patients, presenting challenges in treatment due to its antibiotic resistance and environmental persistence.
Advancing Infection Prevention With Diagnostic Innovation: Insights From Alesia McKeown, PhD
September 17th 2024Alesia McKeown, PhD, discusses the pivotal role of cutting-edge diagnostic technologies in enhancing infection prevention, especially in high-risk health care environments, during an interview with Infection Control Today.
The Role of Accurate Testing in Preventing Respiratory Illnesses: Insights from Dr. Aparna Ahuja
September 17th 2024On Get Ready for Flu Day, Dr. Aparna Ahuja discusses the importance of accurate respiratory illness testing, the risks of self-diagnosis, and the role of infection prevention personnel in public health education.
How Cleaning Medical Equipment Directly Affects Patient Safety and Equipment Longevity
September 16th 2024Hospital-associated infections affect over 1 million US patients annually. Proper medical equipment cleaning and sterilization significantly reduce infection risks, improving patient outcomes and safety.
Top 3 Secrets to Effective Infection Prevention and Control Through Strategic MDRO Surveillance
September 13th 2024Sean Brown’s 2024 Disease Prevention Summit presentation emphasized leveraging technology, prioritizing high-risk patients, and environmental surveillance to enhance infection prevention and control strategies.